Biogen Pulls Application for Alzheimer's Drug in Europe
Biogen said on Friday it will withdraw the marketing application for its controversial Alzheimer's drug, aducanumab, in Europe after the US biotech company failed to convince the European regulator of the treatment's benefits.
Reuters Health Information
source https://www.medscape.com/viewarticle/972612?src=rss
Reuters Health Information
source https://www.medscape.com/viewarticle/972612?src=rss
Comments
Post a Comment